Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of guselkumab via the SelfDose device in moderate to severe plaque psoriasis
2016-002022-37Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis and psoriasis comparing Guselkumab with Placebo (2 arms). Primary endpoint: Co-primary endpoints. Started Aug 2016; status: completed.
02
Drugs
guselkumab
03
Conditions
plaque psoriasispsoriasis
Beyond the preview
Go deeper on 2016-002022-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002022-37.